60O First-in-human phase I evaluation of HCB301, a tri-specific SIRPα-PD-1-TGFβ fusion protein: Safety, pharmacokinetics, and multisystem immune activation
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
HCB301 is an engineered tri-specific IgG4 fusion protein designed to overcome immune resistance by blocking the SIRPα-CD47 innate checkpoint, inhibiting PD-1/PD-L1-mediated T-cell suppression, and neutralizing TGFβ. This design aims to activate macrophage phagocytosis, restore T-cell effector function, and remodel immune-excluded tumor microenvironments. Preclinical studies confirmed activity across all three pathways with innate and adaptive immune activation while preserving hematologic safety.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Phagocytosis and Immune Regulation
Immunotherapy and Immune Responses
Publication details
- Journal / source
- ESMO Open
- Volume
- 11
- Pages
- 106201–106201
- Publication date
- 1 April 2026
- Language
- EN